Share
1,890 Posts.
lightbulb Created with Sketch. 3
clock Created with Sketch. 03/08/16
21:04
Share
Originally posted by imspartacus
↑
Very pleasing result IMO. Whilst the cash generated was a bit lower than where I’d thought they come in at (when excluding the $135k payment), The potential is there and they’re growing a nice post Medivet business. Given the slightly chunky nature of a number of contracts (– especially in the Clements space for their centrifuges and pumps) this could easily be more based on timing of deals. As the business matures the revenue should smooth out further. “During the quarter MLA witnessed encouraging sales growth, in particular with the TUTA range of products into the Australian healthcare system, This has been an ongoing focus for the Company, as growth in sales of its own products will make the business less reliant on OEM contracts and further boost gross margins.” very encouraging, and whilst cash generated excluding the Medivet payment was $136k, there is potential to increase margins further.would result in an after tax profit of 500k which would have the company trading around a PE of 12. This is pretty decent overall, when considering the cash burn of Medivet and costs of disposal incurred in the 1st Quarter.“The Company anticipates that the business will continue to be cash flow positive in future quarters.”
Expand
Seriously your clutching at straws here....it's a typical mediocre ASX co. Do you remember the MediVet presentations when they bagged the existing businesses and talked up the acquisition as the future of the co.?
